Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Bemarituzumab in solid tumors

Daniel Catenacci, MD, University of Chicago, Chicago, IL, describes a Phase Ib escalation and expansion study of bemarituzumab, an anti-FGFR2 monoclonal antibody, in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).